{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-042867","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.439813+00:00","generated_at":"2026-05-30T09:25:27.931416+00:00","sec_items":["5.02","8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"CFO Mark Andersen resigns; Board member Robert Hoffman appointed Interim CFO","bullets":["Mark Andersen resigns as CFO effective up to Nov 15, 2024; will transition duties.","Robert Hoffman, current Board member, appointed Interim CFO effective Oct 30, 2024.","Hoffman receives $45,833/month cash compensation; steps down from Audit/Compensation Committees.","Richard Cilento becomes Audit Committee Chairman; Stacy Coen joins Audit; Matthew Link leads Compensation Committee.","Andersen eligible for nine months base salary severance plus COBRA reimbursement on signing release."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-042867","json":"https://secwatch.observer/filing/0001493152-24-042867.json","markdown":"https://secwatch.observer/filing/0001493152-24-042867.md","text":"https://secwatch.observer/filing/0001493152-24-042867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224042867/0001493152-24-042867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224042867/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:25:27.931416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f53cb591ae","claim":"Mark Andersen resigned as Chief Financial Officer at FibroBiologics, Inc..","evidence_excerpt":"On October 25, 2024, Mr. Mark Andersen informed FibroBiologics, Inc. (the “Company”) of his decision to voluntarily resign from his position as the Company’s Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224042867/0001493152-24-042867-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}